1. Xu XR, Yousef GM, Ni H: Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood 2018, 131(16):1777-1789.
2. Sylman JL, Boyce HB, Mitrugno A, Tormoen GW, Thomas IC, Wagner TH, Lee JS, Leppert JT, McCarty OJT, Mallick P: A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients. Sci Rep 2018, 8(1):6564.
3. Zu R, Yu S, Yang G, Ge Y, Wang D, Zhang L, Song X, Deng Y, He Q, Zhang K et al: Integration of platelet features in blood and platelet rich plasma for detection of lung cancer. Clin Chim Acta 2020, 509:43-51.
4. Rachidi S Md P, Kaur MM, Lautenschlaeger TM, Li Z Md P: Platelet count correlates with stage and predicts survival in melanoma. Platelets 2019, 30(8):1042-1046.
5. Hu Q, Hada A, Han L: Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer. J Ovarian Res 2020, 13(1):78.
6. Meikle CK, Kelly CA, Garg P, Wuescher LM, Ali RA, Worth RG: Cancer and Thrombosis: The Platelet Perspective. Front Cell Dev Biol 2016, 4:147.
7. Schulman S: How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood 2017, 129(25):3285-3293.
8. Leblanc R, Peyruchaud O: Metastasis: new functional implications of platelets and megakaryocytes. Blood 2016, 128(1):24-31.
9. Li N: Platelets in cancer metastasis: To help the "villain" to do evil. Int J Cancer 2016, 138(9):2078-2087.
10. Cho MS, Bottsford-Miller J, Vasquez HG, Stone R, Zand B, Kroll MH, Sood AK, Afshar-Kharghan V: Platelets increase the proliferation of ovarian cancer cells. Blood 2012, 120(24):4869-4872.
11. Battinelli EM, Markens BA, Kulenthirarajan RA, Machlus KR, Flaumenhaft R, Italiano JE, Jr.: Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response. Blood 2014, 123(1):101-112.
12. Farooqi AA, Siddik ZH: Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape. Cell Biochem Funct 2015, 33(5):257-265.
13. Holmes CE, Levis JE, Schneider DJ, Bambace NM, Sharma D, Lal I, Wood ME, Muss HB: Platelet phenotype changes associated with breast cancer and its treatment. Platelets 2016, 27(7):703-711.
14. Paolacci S, Precone V, Acquaviva F, Chiurazzi P, Fulcheri E, Pinelli M, Buffelli F, Michelini S, Herbst KL, Unfer V et al: Genetics of lipedema: new perspectives on genetic research and molecular diagnoses. Eur Rev Med Pharmacol Sci 2019, 23(13):5581-5594.
15. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z: GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 2017, 45(W1):W98-w102.
16. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK: Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun 2019, 10(1):1523.
17. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013, 4:2612.
18. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD et al: The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015, 21(8):938-945.
19. Su L, Zhang G, Kong X: Prognostic Significance of Pregnancy Zone Protein and Its Correlation with Immune Infiltrates in Hepatocellular Carcinoma. Cancer Manag Res 2020, 12:9883-9891.
20. Zhang G: Expression and Prognostic Significance of BANF1 in Triple-Negative Breast Cancer. Cancer Manag Res 2020, 12:145-150.
21. Reinhold WC, Sunshine M, Liu H, Varma S, Kohn KW, Morris J, Doroshow J, Pommier Y: CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res 2012, 72(14):3499-3511.
22. Colwill K, Gräslund S: A roadmap to generate renewable protein binders to the human proteome. Nat Methods 2011, 8(7):551-558.
23. Nusinow DP, Szpyt J, Ghandi M, Rose CM, McDonald ER, 3rd, Kalocsay M, Jané-Valbuena J, Gelfand E, Schweppe DK, Jedrychowski M et al: Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell 2020, 180(2):387-402.e316.
24. Schlesinger M: Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol 2018, 11(1):125.
25. Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, Schellen P, Verschueren H, Post E, Koster J et al: RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell 2015, 28(5):666-676.
26. Lin RJ, Afshar-Kharghan V, Schafer AI: Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood 2014, 124(2):184-187.
27. Labelle M, Begum S, Hynes RO: Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011, 20(5):576-590.
28. Placke T, Salih HR, Kopp HG: GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. J Immunol 2012, 189(1):154-160.
29. Azimi I, Petersen RM, Thompson EW, Roberts-Thomson SJ, Monteith GR: Hypoxia-induced reactive oxygen species mediate N-cadherin and SERPINE1 expression, EGFR signalling and motility in MDA-MB-468 breast cancer cells. Sci Rep 2017, 7(1):15140.
30. Mazzoccoli G, Pazienza V, Panza A, Valvano MR, Benegiamo G, Vinciguerra M, Andriulli A, Piepoli A: ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. J Cancer Res Clin Oncol 2012, 138(3):501-511.
31. Klimczak-Bitner AA, Kordek R, Bitner J, Musiał J, Szemraj J: Expression of MMP9, SERPINE1 and miR-134 as prognostic factors in esophageal cancer. Oncol Lett 2016, 12(5):4133-4138.
32. Liao P, Li W, Liu R, Teer JK, Xu B, Zhang W, Li X, McLeod HL, He Y: Genome-scale analysis identifies SERPINE1 and SPARC as diagnostic and prognostic biomarkers in gastric cancer. Onco Targets Ther 2018, 11:6969-6980.
33. Zhang Q, Lei L, Jing D: Knockdown of SERPINE1 reverses resistance of triple‑negative breast cancer to paclitaxel via suppression of VEGFA. Oncol Rep 2020, 44(5):1875-1884.
34. Mao Y, Li W, Hua B, Gu X, Pan W, Chen Q, Xu B, Wang Z, Lu C: Silencing of ELK3 Induces S-M Phase Arrest and Apoptosis and Upregulates SERPINE1 Expression Reducing Migration in Prostate Cancer Cells. Biomed Res Int 2020, 2020:2406159.
35. Lorenzi L, Tabellini G, Vermi W, Moratto D, Porta F, Notarangelo LD, Patrizi O, Sozzani S, de Saint Basile G, Latour S et al: Occurrence of nodular lymphocyte-predominant hodgkin lymphoma in hermansky-pudlak type 2 syndrome is associated to natural killer and natural killer T cell defects. PLoS One 2013, 8(11):e80131.
36. Miao Y, Zhu HY, Qiao C, Xia Y, Kong Y, Zou YX, Miao YQ, Chen X, Cao L, Wu W et al: Pathogenic Gene Mutations or Variants Identified by Targeted Gene Sequencing in Adults With Hemophagocytic Lymphohistiocytosis. Front Immunol 2019, 10:395.
37. Zhang J, Cheng J, Zeng Z, Wang Y, Li X, Xie Q, Jia J, Yan Y, Guo Z, Gao J et al: Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma. Oncotarget 2015, 6(39):42040-42052.
38. Xie T, Guo X, Wu D, Li S, Lu Y, Wang X, Chen L: PAFAH1B3 Expression Is Correlated With Gastric Cancer Cell Proliferation and Immune Infiltration. Front Oncol 2021, 11:591545.
39. Xu J, Zang Y, Cao S, Lei D, Pan X: Aberrant expression of PAFAH1B3 associates with poor prognosis and affects proliferation and aggressiveness in hypopharyngeal squamous cell carcinoma. Onco Targets Ther 2019, 12:2799-2808.
40. Fan J, Yang Y, Qian JK, Zhang X, Ji JQ, Zhang L, Li SZ, Yuan F: Aberrant Expression of PAFAH1B3 Affects Proliferation and Apoptosis in Osteosarcoma. Front Oncol 2021, 11:664478.
41. Kumari R, Majumder MM, Lievonen J, Silvennoinen R, Anttila P, Nupponen NN, Lehmann F, Heckman CA: Prognostic significance of esterase gene expression in multiple myeloma. Br J Cancer 2021, 124(8):1428-1436.